Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation.
about
Phosphodiesterase 4-targeted treatments for autoimmune diseasesScience review: Redox and oxygen-sensitive transcription factors in the regulation of oxidant-mediated lung injury: role for nuclear factor-kappaBThe role of phosphodiesterase-5 inhibitors in prostatic inflammation: a reviewOveractive bladder syndrome and the potential role of prostaglandins and phosphodiesterases: an introductionSynthesis, Structural Analysis, and Biological Evaluation of Thioxoquinazoline Derivatives as Phosphodiesterase 7 InhibitorsPDE 7 inhibitors: new potential drugs for the therapy of spinal cord injuryUpdate on the therapeutic potential of PDE4 inhibitors.Myelin-derived lipids modulate macrophage activity by liver X receptor activationThe absence of mrp4 has no effect on the recruitment of neutrophils and eosinophils into the lung after LPS, cigarette smoke or allergen challenge.PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalizationErectogenic Effects of Clerodendron capitatum: Involvement of Phosphodiesterase Type-5 Inhibition.Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors.Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease.Clinical and molecular genetics of the phosphodiesterases (PDEs).New methods for the discovery and synthesis of PDE7 inhibitors as new drugs for neurological and inflammatory disorders.The role of phosphodiesterases in bladder pathophysiology.Apremilast for the treatment of psoriatic arthritis.Kaempferia parviflora, a plant used in traditional medicine to enhance sexual performance contains large amounts of low affinity PDE5 inhibitors.Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patientsA cyclic nucleotide PDE5 inhibitor corrects defective mucin secretion in submandibular cells containing antibody directed against the cystic fibrosis transmembrane conductance regulator protein.Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL-10-deficient mice.The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo.Effects of dialkoxylphenyl compounds with oxime group on macrophage function and the proliferation of lymphocytes.PDE4 inhibitor rolipram inhibits the expression of microsomal prostaglandin E synthase-1 by a mechanism dependent on MAP kinase phosphatase-1.Phosphodiesterase type 5 and cancers: progress and challenges.Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast.Effect of bucladesine, pentoxifylline, and H-89 as cyclic adenosine monophosphate analog, phosphodiesterase, and protein kinase A inhibitor on acute pain.Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species.
P2860
Q21245284-D67DFE44-4F2A-4601-A64F-71FC8E9C5424Q24791031-39BA84CB-1CAF-44D3-8D92-E69EBFD78424Q26785428-2BABE767-FC3F-4D95-81C1-3B49F3590984Q27011502-0447DB10-67D8-432E-8CB6-B7BB4F07E455Q27654567-1E08C4B9-EFF2-4D20-8E87-8B0A39D71C08Q28477025-B6F1ED15-F559-4AF1-B094-04339B70FFE3Q34107488-0C035E22-A2E4-4A3E-8CEC-B876A7DC642BQ34416303-615C2759-3BDE-48C8-A363-D30A5FB7F86EQ34684137-02F4138F-6274-4B3D-ABD8-09368ABB94FCQ35005680-548D27D6-3582-409F-9806-A6A81EAFFC39Q35070459-7FEF1692-B3EA-4206-A5B0-57D728D4A3F8Q36061710-4747913B-B698-44CF-9C85-F5267BE8E272Q37129351-19AEBF78-1030-4589-A394-7DACBE21BDFDQ37657841-945F7BA1-2E01-4598-9502-DA09E5FC80FCQ38097492-5BBD57A8-1BCD-46FB-8CAA-B06DFAC6A977Q38106628-1FD3A57D-DEC2-41E1-8383-186A66BA297BQ38202205-C28406A5-C536-4452-8AA7-4806F5946B03Q40668587-A63A3B23-E92C-448C-A5DD-4C0E739345EEQ41837804-00B90D88-5CA5-41DA-8C99-D9090FE6EFCEQ42481546-A3FE70A1-D504-4799-BE4F-027E99FE5070Q43766971-FD5BCA38-FEB6-431C-91AD-AFA286F4EA4BQ43897053-CA47D673-1AE5-4354-86EC-7961E129D969Q44852650-3CDC1F7F-E0F8-4F44-9025-AD29AA4D7A00Q47103017-C62842CA-7518-4A55-B172-808EF64DA16AQ47171803-47D76D1D-1AF1-4A6B-B81D-9463680289C9Q47682869-E617F444-836A-4469-AA3E-DCF7A1654F41Q48154251-C6E2C90D-05C8-4D77-AB33-A7E0CA2F3B6FQ53872083-E6E03641-7BAA-426D-B9CC-AA6C17937ED5
P2860
Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation.
@ast
Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation.
@en
type
label
Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation.
@ast
Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation.
@en
prefLabel
Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation.
@ast
Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation.
@en
P1476
Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation.
@en
P2093
Essayan DM
P304
P356
10.1016/S0006-2952(98)00331-1
P407
P577
1999-05-01T00:00:00Z